Online citations, reference lists, and bibliographies.
← Back to Search

Patient And Physician Preferences For Oral Pharmacotherapy For Overactive Bladder: Two Discrete Choice Experiments

M. Heisen, S. Baeten, B. Verheggen, M. Stoelzel, Z. Hakimi, A. Ridder, R. van Maanen, E. Stolk
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Objective We examined patient and treating physician (general practitioners, urologists, and [uro]gynecologists) preferences for oral pharmacotherapy (antimuscarinics and beta-3 adrenoceptor agonists) for overactive bladder to gain a deeper understanding of which attributes drive their treatment decision-making and to quantify to what extent. Research design and methods Two separate discrete choice experiments were developed and validated using the input of patients and physicians. The patient experiment contained the following attributes: micturition frequency, incontinence, nocturia, urgency, dry mouth, constipation, increased heart rate, and increased blood pressure. The physician experiment contained two additional attributes: coping and atrial fibrillation. Both were fielded in five European countries. To allow for preference heterogeneity, utility functions were estimated using a mixed multinomial logit model. Results A total of 442 patient and 318 physician responses were analyzed. Patients ranked the attributes based on their largest potential impact on treatment value as follows: incontinence, nocturia, risk of an increased heart rate, urgency, frequency, risk of increased blood pressure, risk of constipation, and risk of dry mouth; and physicians as follows: incontinence, urgency, nocturia, frequency, risk of dry mouth, coping, risk of increased heart rate, risk of increased blood pressure, risk of atrial fibrillation, and risk of constipation. Conclusion and limitations In their valuations, physicians put more emphasis on increasing benefits, whereas patients put more emphasis on limiting risks of side effects. Another contrast that emerged was that patients’ valuations of side effects were found to be fairly insensitive to the presented risk levels (with the exception of risk of dry mouth), whereas physicians’ evaluated all side effects in a risk-level dependent manner. The obtained utility functions can be used to predict whether, to what extent, and for which reasons patients and physicians would choose one oral pharmacotherapy over another, as well as to advance shared decision-making.
This paper references
Summary of Product Characteristics, Vesicare 5mg & 10mg (Dutch)
Astellas
10.1007/s00345-002-0301-4
Prevalence and burden of overactive bladder in the United States
W. Stewart (2002)
Summary of Product Characteristics, Betmiga 25mg & 50mg (Dutch)
Astellas (2014)
10.1067/MOB.2002.125704
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.
P. Abrams (2003)
10.1136/bmj.320.7248.1530
Using conjoint analysis to elicit preferences for health care
M. Ryan (2000)
10.1111/j.1464-410X.2005.05835.x
An epidemiological survey of overactive bladder symptoms in Japan
Y. Homma (2005)
10.1016/j.jval.2012.08.2223
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.
F. Reed Johnson (2013)
10.1046/j.1464-410x.2001.02228.x
How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study
I. Milsom (2001)
10.1023/A:1007744326393
Insensitivity to the Value of Human Life: A Study of Psychophysical Numbing
David Fetherstonhaugh (1997)
10.1111/j.1464-410X.2004.04606.x
Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
C. Chapple (2004)
10.1023/A:1016370925601
Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q
K. Coyne (2004)
10.1007/s11136-008-9428-0
The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis
T. Young (2008)
Health and Human Services Food and Drug Administration. Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling
HEISEN (2015)
10.1111/j.1464-410X.2010.09882.x
Preferences for antimuscarinic therapy for overactive bladder
P. Swinburn (2011)
10.1515/9783110208856.233
Declaration of Helsinki. Ethical principles for medical research involving human subjects.
World Medical Association (WMA) (2009)
10.1097/SPV.0b013e318223c8ad
Patient Preferences for Different Severities of and Treatments for Overactive Bladder
J. Wu (2011)
Insensitivity to the value of human life : a study of psychological numbing
D Featherstonhaugh (1997)
10.1016/J.JURO.2007.08.006
The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
S. Harpe (2007)
10.1016/j.jval.2010.11.013
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.
J. Bridges (2011)
10.1016/J.EURURO.2006.01.007
The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
K. Coyne (2006)
10.1111/ijcp.12194
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
V. Nitti (2013)
10.1097/01.JU.0000140957.31325.7F
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
V. Watson (2004)
10.3109/07853890109002087
EQ-SD: a measure of health status from the EuroQol Group
Rosalind Rabin (2001)
10.1016/j.eururo.2014.01.019
What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women
A. Agarwal (2014)
10.1016/j.juro.2012.09.079
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
E. Gormley (2012)
ISN/Protocol 178-CL-102, Master Informed Consent Form
B V Astellas Pharma Europe (2012)
10.1002/NAU.20367
Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients
M. Michel (2007)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
Christiane (2004)
10.1111/j.1464-410X.2009.08846.x
Reliability and normal ranges for the Patient’s Perception of Intensity of Urgency Scale in asymptomatic women
R. Cartwright (2010)
10.1023/A:1007796310463
Confusion of Relative and Absolute Risk in Valuation
J. Baron (1997)
10.2165/00019053-199304050-00006
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Margaret C. Reilly (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar